13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001825034
Total reported value
$439.8M
$439.8M
10 檔
87.1%
In Q1 2026, Euclidean Capital LLC's U.S. equity holdings reached a combined market value of $439.8M, distributed across 10 disclosed stock positions.
In Q1 2026, Euclidean Capital LLC adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VEU | Vanguard Ftse All-world Ex-u | ETF-Other | 62.09% | -0.33% | +8.47% | |
| 2 | VTV | Vanguard Value ETF | ETF-Other | 26.01% | -0.25% | — | |
| 3 | INDA | Ishares Msci India ETF | ETF-Other | 4.41% | -0.26% | — | |
| 4 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.20% | -0.76% | — | |
| 5 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.92% | -0.17% | — | |
| 6 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.83% | -0.03% | — | |
| 7 | ALEC | Alector Inc | Stock-Other | 0.72% | -0.12% | — | |
| 8 | SRZN | Surrozen Inc | Stock-Other | 0.65% | -0.13% | — | |
| 9 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.18% | -0.01% | — | |
| 10 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VEU | Vanguard Ftse All-world Ex-u | +2.6% | +8.47% | Add |
| 2 | ORIC | Oric Pharmaceuticals Inc | +1% | — | Unchanged |
| 3 | ALEC | Alector Inc | +0.2% | — | Unchanged |
| 4 | SRZN | Surrozen Inc | +0.1% | — | Unchanged |
| 5 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 6 | TNYA | Tenaya Therapeutics Inc | 0% | — | Unchanged |
| 7 | PMVP | Pmv Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 8 | FHTX | Foghorn Therapeutics Inc | -0.4% | — | Unchanged |
| 9 | VTV | Vanguard Value ETF | -0.9% | — | Unchanged |
| 10 | INDA | Ishares Msci India ETF | -1% | — | Unchanged |
| 11 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | EXIT | Sold out |
| 12 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Euclidean Capital LLC reported a total U.S. public equity portfolio value of $439.8M across 10 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VEU, VTV, INDA) accounted for 87.1% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
SPY
前期市值: $2.8M
During Q1 2026, Euclidean Capital LLC's top holdings by market value included VEU (62.1%)、VTV (26.0%)、INDA (4.4%). The largest single position, VEU, represented 62.1% of total portfolio value.
In Q1 2026, Euclidean Capital LLC made 3 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.